1085706-41-7

Upstream product

• 1085706-40-6 (S)-tert-butyl 2-(5-(4-iodophenyl)-1H-pyrazol-3-yl)pyrrolidine-1-carboxylate 
• 1085706-38-2 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-pyrazol-3-yl)pyrrolidine-1-carboxylate 
• 766-96-1 4-bromo-1-ethynylbenzene 
• 1085706-37-1 (S)-tert-butyl 2-(3-(4-bromophenyl)propioloyl)pyrrolidine-1-carboxylate 
• 1085706-39-3 (S)-tert-butyl 2-(3-(4-iodophenyl)propioloyl)pyrrolidine-1-carboxylate 
• 766-99-4 1-ethynyl-4-iodobenzene 
• 134856-58-9 1-iodo-4-(trimethylsilylethynyl)benzene 

Downstream Products

• 1085706-55-3 dimethyl-(1R,1'R)-2,2'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(1H-pyrazole-5,3-diyl))bis(pyrrolidine-2,1-diyl))bis(2-oxo-1-phenylethane-2,1-diyl)dicarbamate 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein A and B are each phenyl; D and E are each five-membered aromatic rings containing one, two, or three i hcteroatoms independently selected from nitrogen, oxygen, and sulfur; provided that ', at least one of D and E is other than imidazole; compositions and methods for the treatment of Hepatitis C virus (HCV) inf ection. Also disclosed are pharmaceutical compositions containing such compounds and methods f or using these compounds in the treatment of HCV inf ection.